F-1/A: Otsaw Limited Files Amended IPO Prospectus, Details Robotics Growth Strategy and Financials Amidst Losses

Otsaw Limited, a Singapore-based autonomous mobile robot and robotics solutions company, has filed an amended F-1 registration statement for its initial public offering on Nasdaq, outlining its business, financial performance, and growth strategies despite a history of net losses and working capital deficits.

Summary

• Otsaw Limited specializes in Autonomous Mobile Robots (AMRs) and robotics solutions, focusing on security, disinfection, last-mile delivery, and healthcare facilities management.
• The company reported revenues of US$5.3 million for the fiscal year ended April 30, 2024, and US$5.1 million for the fiscal year ended April 30, 2023.
• Net losses were US$6.5 million for FY2024 and US$6.7 million for FY2023.
• For the six months ended October 31, 2024, revenues were US$1.8 million, down from US$2.8 million in the same period of 2023, with net losses of US$3.3 million and US$2.9 million respectively.
• The company has a net working capital deficit of US$12,399,036 as of October 31, 2024, and accumulated losses of US$25,108,914.
• Otsaw's revenue streams include service and maintenance (79.3% of total revenue in FY2024), sales of robots (18.0%), and Robot as a Service (RaaS) (2.7%).
• The company's gross profit margin increased to 31.6% in FY2024 from 24.7% in FY2023, driven by increased service prices, better cost controls, and new-generation products.
• Otsaw is developing its Autonomous Navigation System (ANS) Version 3, 'Odyssey,' for commercialization to the broader AMR and robotics industry.
• The company plans to expand its production capacity to 15 units per month by Q3 2025 and increase its production workforce by 300%.
• Otsaw aims to expand its global market presence in security and healthcare facilities management, particularly in the United States, Canada, UK, Australia, and GCC countries.
• The company has a joint venture with Swisslog Healthcare for hospital intralogistics solutions, with Otsaw Swisslog Healthcare Robotics Pte. Ltd. becoming 100% owned by Otsaw Technology Solutions Pte. Ltd. as of January 20, 2025.
• The next-generation TransCar 5.0 AGV, empowered by Otsaw's proprietary software, is expected to launch production in 2025 with commercial deployment targeted for Q1 2026.
• Otsaw has secured a US$2 million contract with a public hospital in Singapore for TransCar AGVs, with remaining payments of S$1,121,533 due upon installation completion (expected October 30, 2025) and user acceptance test completion (expected March 30, 2026).
• The company has granted underwriters an option to purchase up to 666,667 additional Class A Ordinary Shares at the IPO price less underwriting discounts.
• Mr. Ling Ting Ming, the CEO, will control approximately 63.4% of the total voting power post-IPO, making Otsaw a controlled company under Nasdaq rules.

Sentiment

Score: 3

Explanation: The company is in a challenging financial position with recurring and increasing net losses, significant working capital deficits, and negative operating cash flow, raising substantial doubt about its going concern ability. While it has innovative products, strategic partnerships, and ambitious growth plans, the current financial performance and reliance on external funding for operations indicate high risk and uncertainty.

Positives

• Otsaw is an early-mover in the facilities management AMR and robotics solutions market, with established international channels and direct customers in over 20 countries.
• The company possesses cutting-edge software technologies, including patented 3D SLAM, Sensor Fusion, and Machine Perception, enabling advanced outdoor autonomy.
• Otsaw's products are highly scalable, with a wide array of solutions for security, disinfection, last-mile delivery, and healthcare.
• Strategic partnerships, such as the joint venture with Swisslog Healthcare, provide immediate market access and leverage existing customer bases in high-barrier-to-entry sectors like healthcare.
• The development of ANS Version 3, 'Odyssey,' aims to position Otsaw as a prominent AI and AMR software solution provider to the entire robotics industry, opening new monetization opportunities.
• Planned expansion of production capacity to 15 units per month by Q3 2025 and a 300% increase in production workforce are expected to lead to cost efficiencies and competitive pricing.
• Gross profit margin increased from 24.7% in FY2023 to 31.6% in FY2024, indicating improved profitability on sales and services.
• The company has a visionary, proven, and experienced management team with extensive industry expertise.

Negatives

• Otsaw is an early-stage company with a history of recurring net losses, reporting US$6.5 million in FY2024 and US$3.3 million for the six months ended October 31, 2024.
• There is substantial doubt about the company's ability to continue as a going concern due to continuing losses from operations and limited working capital deficit of US$12,399,036 as of October 31, 2024.
• The company has yet to achieve positive operating cash flow, with negative cash flow from operating activities of US$2.3 million in FY2024 and US$1.5 million for the six months ended October 31, 2024.
• Revenue for the six months ended October 31, 2024, decreased by 35.8% compared to the same period in 2023, primarily due to lower AGV deployment and sales transition.
• The RaaS revenue stream declined significantly by 42.9% in FY2024 due to decreased demand for pandemic-driven solutions (O-RX and O-R2 leases) and rapid technological advancements.
• Sales of robots decreased by 48.9% for the six months ended October 31, 2024, due to phasing out of existing models and new models not yet being on sale.
• General and administrative expenses increased by 6.7% for the six months ended October 31, 2024, mainly due to IPO activity-related spending and increased headcount.
• Finance costs significantly increased by 103% from US$0.7 million in FY2023 to US$1.4 million in FY2024, primarily due to higher interest rates on director loans.
• The company relies solely on Reis Robotics as a single-source supplier for TransCar systems until June 30, 2025, posing supply chain risks.
• The management team lacks experience in managing a U.S. public company, which could lead to compliance challenges and diversion of attention.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses and limited working capital.
• Inability to achieve positive operating cash flow, potentially requiring additional financing that may result in dilution or significant debt obligations.
• Significant investments in research and development may not yield expected returns or market acceptance for new products.
• Limited operating history makes it difficult to evaluate business viability and increases investment risk.
• Unproven ability to manufacture, assemble, and produce products on a large scale, leading to potential delays and cost overruns.
• The commercial robotic market is in early stages of customer adoption, and broad acceptance in facilities management is unproven, risking slow sales growth.
• Difficulty in accurately forecasting consumer demand and managing inventory effectively could materially impact operating results and financial condition.
• Targeting large corporations with substantial negotiating power and competitive internal solutions may adversely affect sales and operations.
• Dependence on a small number of key customers for a significant portion of service and maintenance revenue, with risk of non-renewal or loss of major customers.
• Difficulties expanding operations into new regions or countries due to unfamiliarity with local regulations, economic conditions, and labor dynamics.
• Operating in a rapidly evolving and competitive industry, with risk of market share decline due to technological evolution and competitors with greater resources.
• Dependence on the global supply chain and single/limited source suppliers, leading to potential constraints, cost increases, and production delays.
• Increases in costs, disruption of supply, or shortage of critical materials like lithium-ion cells or semiconductors could harm business.
• Reliance solely on Reis Robotics for TransCar systems until June 30, 2025, poses risks of supply delays and revenue loss if the relationship is impaired.
• Inability to build and maintain the Otsaw brand, or negative publicity, could adversely affect product acceptance and revenues.
• Limited experience operating robots in diverse environments, increasing the likelihood of collisions, liability, and negative publicity.
• Design flaws, defects, errors, or malfunctions in products or software could result in recalls, claims, injuries, property damage, and reputational harm.
• Subject to stringent and changing data privacy and security laws, regulations, and standards across multiple jurisdictions, leading to compliance costs and potential liabilities.
• Cybersecurity risks to operations, IT infrastructure, and product software could result in data loss, intellectual property compromise, and reputational damage.
• Acquisitions, joint ventures, or other investments may negatively affect operating results, cause dilution, or increase debt if not successfully integrated.
• Failure to effectively manage significant business and operational expansion could materially and adversely affect financial results.
• Risks associated with strategic alliances, such as the joint venture with Swisslog Healthcare, including sharing proprietary information, non-performance by partners, and integration challenges.
• The right of Swisslog Healthcare to require Otsaw to purchase its equity interests in the Otsaw-Swisslog JV could adversely affect liquidity and financial condition.
• Loss of key personnel or inability to attract and retain highly qualified talent could harm the business.
• Developments in the social, political, regulatory, and economic environment, including natural events, wars, and health epidemics, may adversely impact operations.
• Global economic conditions could materially adversely impact demand for products and services.
• Exposure to foreign exchange risk due to international operations and fluctuations in currency exchange rates.
• Imposition of trade barriers, escalation of trade disputes, and changes to trade policy could adversely affect business.
• Subject to anti-corruption, anti-bribery, anti-money laundering, and sanctions laws, with noncompliance leading to fines and reputational damage.
• Failure of internal controls over financial reporting could harm business and financial results.
• Environmental laws and regulations and unforeseen costs could negatively impact future earnings.
• Inability to obtain and maintain intellectual property protection, or future intellectual property claims, could limit technology use and incur significant costs.
• Use of other parties' software, including open source, could lead to disclosure requirements or costly re-engineering.
• The dual-class share structure concentrates voting control with the CEO, limiting public shareholders' influence.
• As a controlled company, the company may rely on Nasdaq exemptions from corporate governance rules, affording less protection to public shareholders.
• The dual-class structure may adversely affect the trading market for Class A Ordinary Shares.
• Class A Ordinary Shares may be thinly traded, limiting liquidity and ability to sell shares.
• No prior public market for Class A Ordinary Shares, risking inability to resell at or above IPO price.
• Failure to satisfy or continue to satisfy Nasdaq listing requirements could negatively impact share price and liquidity.
• Nasdaq may apply more stringent listing criteria due to small public offering and large insider holdings.
• The trading price of Class A Ordinary Shares may be volatile, leading to substantial losses.
• Exercise of options under the 2025 Share Incentive Plan may result in dilution to shareholders.
• Lack of consistent research coverage or negative analyst reports could cause share price decline.
• Short selling may drive down the market price of Class A Ordinary Shares.
• Broad discretion in the use of IPO net proceeds may not be effective.
• No expected dividends in the foreseeable future, relying solely on price appreciation for investment return.
• Future sales of substantial amounts of Class A Ordinary Shares could adversely affect market price.
• Immediate and substantial dilution for new investors.
• Increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• As a Cayman Islands company, shareholder rights may be more limited than those of U.S. company shareholders.
• Judgments obtained against the company by shareholders may not be enforceable in the Cayman Islands or Singapore.
• Cayman Islands economic substance requirements may affect business and operations.
• Reduced disclosure requirements as an emerging growth company may make Class A Ordinary Shares less attractive.
• As a foreign private issuer, disclosure obligations differ from U.S. domestic reporting companies, offering less protection to investors.
• Potential classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes could lead to adverse tax consequences for U.S. investors.
• Uncertainty regarding classification as a Singapore tax resident.

Future Outlook

Otsaw Limited plans to advance its core software technologies, commercialize its Autonomous Navigation System (ANS) Version 3 'Odyssey' for the broader AMR and robotics industry, and expand its production capacity for cost-efficient manufacturing. The company intends to increase its global presence in security and healthcare facilities management by expanding its sales and marketing team, strengthening its distribution network, and pursuing strategic alliances, acquisitions, investments, and partnership opportunities. Production of the next-generation TransCar 5.0 is expected to launch in 2025, with commercial deployment targeted for Q1 2026. The company expects to continue incurring operating and net losses for the foreseeable future as it invests in growth.

Management Comments

• Our mission is to disrupt, revolutionize, and redefine the global facilities management industry with our AI-enabled AMRs and robotics solutions across security, disinfection, last-mile delivery, and healthcare facilities.
• We believe the world is entering a new era where AMRs, robotics and AI are becoming increasingly prevalent in the facilities management.
• We aspire to disrupt the facilities management industry with our AI-enabled AMRs and robotics solutions in the realms of security, disinfection, sanitation, last-mile delivery, logistics, and healthcare.
• We believe our RaaS model enables us to deliver significant value to our customer end-users at a low cost.
• We believe our AMRs, UV-C LED disinfections, and intralogistics robotics ecosystems will rapidly expand and continue to play a significant role in this post-pandemic world, where the labor shortage and challenges have been critically exposed, and where the power of automation, robots and AI is being realized in the facilities management industry.
• We believe that our AMRs and robotic solutions will augment and enhance human labor.
• We believe that the O-R3 is able to stand out from similar products of our competitors due to its capabilities in navigating outdoor environment and in industry applications.
• We believe that the TransCar AGV is able to stand out from similar products of our competitors because it is multifunctional and is able to handle food, medication, linen and sterile equipment deliveries.
• We believe that Camello+ is able to stand out from similar products of our competitors because of its modular capabilities, allowing it to be adapted for different use cases, from basic last mile logistics to critical healthcare deliveries.
• We believe the Odyssey, which is empowered by our cutting edge outdoor autonomous software capabilities, will unlock the industry-wide application and tremendous monetization opportunities for our proprietary ANS, core software technologies and robotics outdoor autonomy expertise.
• We believe the world is entering a new era where robots will become increasingly prevalent in all sectors, and thus we believe the Odyssey will expand our ecosystem coverage by integrating our core software technologies with all relevant players in the robotics industry.
• We are confident in our ability to take advantage of current market opportunities because hospitals worldwide are expected to upgrade their intralogistics systems to solve labor shortage and productivity challenges that were particularly exposed during the COVID-19 pandemic.

Industry Context

The global facility management market is projected to grow at an 8.2% CAGR from 2024 to 2032, driven by aging populations, labor shortages, rising wages, and increased demand for automation post-COVID-19. The global robotics market is expected to surpass US$200 billion by 2030 (16.1% CAGR), with significant government and venture capital funding. Healthcare logistics, security robotics, disinfection solutions, and last-mile delivery markets are all experiencing substantial growth, with CAGRs ranging from 7.75% to 30.5%. Otsaw's multi-industry focus and versatile solutions aim to address these growing demands, particularly in automating dangerous, tedious, or repetitive tasks to enhance productivity and reduce human capital reliance.

Comparison to Industry Standards

• Otsaw's O-R3 AMR competes with autonomous security robot developers like Kabam Robotics Pte. Ltd., Ninebot Asia Pte. Ltd., SMP Robotics Singapore Pte. Ltd., Knightscope, Inc., and Robotics Assistance Devices, Inc. Otsaw believes O-R3 stands out due to its outdoor navigation capabilities and industry applications.
• Otsaw's UV-C disinfection systems compete with PBA Robotics Pte. Ltd., Sesto Robotics Pte. Ltd., ST Engineering Ltd., and Pudu Technology. Otsaw highlights its proprietary UV-C LED technology as safer and more effective than traditional mercury-based systems, focusing on hospital-grade cleaning.
• The TransCar AGV faces intense competition from major robotics and automation companies globally, including Oppent S.P.A., Oceaneering International, Inc., Aetheon Inc., Mobile Industrial Robots ApS, DS Automation Ltd., MLR System GmBH, and JBT Corporation. Otsaw believes TransCar AGV's multi-functional capability for food, medication, linen, and sterile equipment deliveries differentiates it.
• Otsaw's Camello+ AMR competes with ground-based unmanned delivery vehicles from Starship Technologies, Kiwi Campus Inc., and Ottonomy.io. Otsaw emphasizes Camello+'s modular capabilities for diverse use cases, from basic logistics to critical healthcare deliveries.
• Otsaw's primary competition remains traditional human labor and facilities management service providers, against whom it aims to demonstrate value proposition and cost-efficiency through increased productivity, labor freeing, and enhanced robot reliability.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings are currently against the company or have been against it, and the company is not aware of investigations being conducted by a governmental entity into the company.

Related Party Transactions

• Sales to related parties (Swisslog Healthcare AG Branch Italy, Swisslog Healthcare AG Branch Netherlands, Swisslog UK, SAS Swisslog France, Activ Technology Group) amounted to US$25,882 in FY2024 and US$102,110 in FY2023.
• Purchases from related parties (Activ Technology Pte Ltd, Serial Microelectronics Pte Ltd, Swisslog Healthcare GmbH, Swisslog Healthcare AG Branch Germany, Swisslog Healthcare AG Branch Netherlands, Meyzer Management Advisory Pte Ltd, SG Networks Pte Ltd) amounted to US$89,361 in FY2024 and US$1,094,195 in FY2023.
• Outstanding loan balance due to Mr. Ling Ting Ming (CEO) was S$6,829,935 (US$5,153,501) as of October 31, 2024, from an oral loan agreement at 12% interest, due on demand.
• Outstanding loan balance due to Mr. Goh Way Siong (shareholder, former director) was US$1,481,482 as of October 31, 2024, from an oral loan agreement at 12% interest, maturing December 31, 2025, and due upon Nasdaq listing.
• Outstanding loan balance due to Serial Microelectronics Pte Ltd (subsidiary of a shareholder) was US$214,650 as of October 31, 2024, from a loan at 24% interest, with maturity date not enforced.
• Outstanding loan balance due to Asian Prosperity Singapore Pte. Ltd. (related party) was S$384,620 (US$290,214) as of October 31, 2024, from a loan at 6% interest, due on demand and upon Nasdaq listing.
• Accrued interest due to Ararrat Capital Pte. Ltd. (company owned by director) of US$1,103,749 as of April 30, 2024, was reclassified to other related parties during the six months ended October 31, 2024.
• Mr. Ling Ting Ming purchased 7,957,700 Class A ordinary shares from minority shareholders for US$5,771,110.62 on July 3, 2025, increasing his beneficial ownership.

Stakeholder Impact

• **Shareholders:** Potential for dilution from future equity raises and the exercise of options. The dual-class share structure concentrates voting power with the CEO, limiting influence for Class A shareholders. Significant accumulated losses and going concern doubt pose a risk to investment value. IPO aims to provide liquidity and capital for growth.
• **Employees:** Expansion plans include a 300% increase in production workforce and additional personnel in sales, marketing, R&D, and customer service, creating job opportunities. However, the company's financial losses and going concern uncertainty could impact job security and future compensation. Share incentive plans aim to incentivize performance.
• **Customers:** New product developments (TransCar 5.0, ANS Version 3 'Odyssey') and expanded production capacity aim to offer more advanced, cost-efficient, and reliable robotics solutions. Increased sales and service teams are intended to improve customer support and market penetration. However, supply chain delays and potential product defects could negatively impact customer satisfaction.
• **Suppliers:** Continued reliance on a global supply chain and single/limited source suppliers creates dependency. Supply chain constraints and cost inflation could affect supplier relationships and payment terms. The transition of TransCar manufacturing in-house will reduce reliance on Reis Robotics.
• **Creditors:** The company has significant outstanding loans from related parties and third parties. The IPO proceeds will be used to repay some loans, which is positive for creditors. However, the company's recurring losses and going concern doubt indicate ongoing financial risk for lenders.

Next Steps

• Complete the initial public offering and list Class A Ordinary Shares on Nasdaq under the symbol OTSA.
• Utilize IPO net proceeds for acquisitions, strategic alliances, joint ventures, production capacity expansion, market expansion, R&D, working capital, and loan repayment.
• Continue to develop core software technologies and commercialize ANS Version 3, 'Odyssey,' with development expected to commence in 2026 and target launch in 2028.
• Expand production capacity to 15 units per month by Q3 2025 and increase production workforce by 300%.
• Launch production of TransCar 5.0 in 2025, with first commercial deployment targeted for Q1 2026.
• Complete installation of TransCar AGVs for the Singapore public hospital contract by October 30, 2025, and user acceptance test by March 30, 2026.
• Obtain UL and FCC certifications for TransCar 5.0 in the United States after CE certification (expected Q2 2026).
• Expand sales and marketing team and distribution network globally, focusing on the United States, Canada, UK, Australia, and GCC countries.
• Continue to identify and qualify alternative suppliers to mitigate single/limited source supplier risks.
• Implement enhanced training programs for new production workforce and adopt lean production methodologies.
• Monitor and evaluate any possible impact of global economic conditions and geopolitical events on business and implement mitigation measures.

Key Dates

Recommendation

Keywords

Autonomous Mobile Robots, Robotics, AI, Facilities Management, Security Robots, Disinfection Systems, Last-Mile Delivery, Healthcare Logistics, AGVs, TransCar, O-R3, Camello+, UV-C LED, Singapore, Nasdaq IPO, SEC Filing, Financial Performance, Net Loss, Working Capital Deficit, Supply Chain, Intellectual Property, Joint Venture, Swisslog Healthcare, Controlled Company, Emerging Growth Company, Foreign Private Issuer